|
| Study | Sample size and duration | NSAID | Treatment group(s) | Visual outcomes | Anatomic outcomes |
|
Soheilian et al.
(2010) [83] | 5 eyes
8 weeks | Diclofenac 500 mcg in 0.1 mL | Diclofenac only (no comparison) | VA improved in 2, worsened in 2, unchanged in 1 | CMT worsened in 4 of 5 at 2 weeks, mean CMT worsened at 8 weeks |
|
Reis Ado et al.
(2010) [85] | 40 eyes
1 month | Ketorolac 500 mcg in 0.1 mL | Ketorolac (20 eyes) versus control (20 fellow eyes) | VA improvement seen in treated eye over fellow eye () | No difference in foveal thickness or macular volume seen between groups |
|
Maldonado et al.
(2011) [86] | 25 eyes
30 days | Ketorolac 3000 mcg in 0.1 mL | Ketorolac only (no comparison) | VA improved ≥5 letters in 28% at 30 days | No significant improvement in macular thickness |
|
Elbendary and Shahin
(2011) [84] | 32 eyes
12 weeks | Diclofenac 500 mcg in 0.1 mL | Diclofenac (16 eyes) versus 4 mg IVT (16 eyes) | No difference in final mean VA or improvement
Only significant improvement in IVT group | Decreased CMT seen in both groups but not significantly different |
|
